Skip to content
OpenCapital
Get started

Recursion Pharmaceuticals, Inc. RXRX Indefinite-Lived Trademarks

Other financials

Income statement

See full
Revenue$6.5M-56.1%
Gross profit-$6.0M+15.0%
Operating income-$128.5M+32.8%
Net income-$117.5M+42.0%
EPS (diluted)-$0.22+56.0%

Balance sheet

See full
Cash & equivalents$665.2M+30.6%
Total debt$88.6M-24.6%
Total equity$1.0B+9.7%
Total assets$1.3B+2.6%

Cash flow

See full
Operating cash flow-$81.1M+38.5%
CapEx$258.0K-85.9%
Free cash flow-$81.4M+39.2%

Valuation

See full
Market cap$1.71B-23.7%
Enterprise value$1.14B-39.8%
P/S25.8×-11.8×

Profitability

See full
Gross margin7.2%—
Operating margin-881.3%-66.8pp
Net margin-842.9%-92.4pp
FCF margin-490.7%-102pp

Returns & leverage

See full
Return on equity-57.2%-14.4pp
Debt / equity0.1×0.0×
Current ratio5.5×+1.4×

Where this comes from

Reported directly by Recursion Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill.

The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Recursion Pharmaceuticals, Inc.'s indefinite-lived trademarks.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s indefinite-lived trademarks?
Recursion Pharmaceuticals, Inc. (RXRX) reported indefinite-lived trademarks of $135.55M in Q1 2026.
How has Recursion Pharmaceuticals, Inc.'s indefinite-lived trademarks changed year-over-year?
Recursion Pharmaceuticals, Inc.'s indefinite-lived trademarks increased by 2.1% year-over-year, from $132.74M to $135.55M.
What is the long-term trend for Recursion Pharmaceuticals, Inc.'s indefinite-lived trademarks?
Over 5 years (2020 to 2025), Recursion Pharmaceuticals, Inc.'s indefinite-lived trademarks has grown at a 173.4% compound annual growth rate (CAGR), from $904K to $138.02M.